For the dose-density comparison , disease-free survival at 5 years was 81 % ( 95 % CI 79-84 ) in patients treated every 2 weeks and 76 % ( 74-79 ) in patients treated every 3 weeks ( HR 077 , 95 % CI 065-092 ; p = 0004 ) ; overall survival rates at 5 years were 94 % ( 93-96 ) and 89 % ( 87-91 ; HR 065 , 051-084 ; p = 0001 ) and for the chemotherapy-type comparison , disease-free survival at 5 years was 78 % ( 75-81 ) in the FEC-P groups and 79 % ( 76-82 ) in the EC-P groups ( HR 106 , 089-125 ; p = 0561 ) ; overall survival rates at 5 years were 91 % ( 89-93 ) and 92 % ( 90-94 ; 116 , 091-146 ; p = 0234 ) .